Targovax ASA announced that Michael Bogenstaetter has been appointed as the company's Chief Business Officer (CBO). He will take up this role in January 2018. Michael joins the company following 25 years' experience in biotech and big pharma. During this time he held senior business development and strategy positions with Sanofi, Novartis and MDS. Michael has also worked as a consultant with The Boston Consulting Group and, most recently, has acted as an independent corporate and business development advisor to some of the world's top pharmaceutical and biotechnology companies.